CSL (CSL) AGM 2025 summary

Opening remarks and agenda

• The meeting opened with a patient story and a welcome to both in-person and online attendees, outlining hybrid meeting procedures and safety protocols.

• Attendees were guided on how to submit questions and participate in voting, both online and in the room.

Financial performance review

• FY2025 revenue rose 5% to $15.6 billion, with NPATA up 14% to $3.3 billion, net profit after tax up 17% to $3 billion, and free cash flow up 58%.

• CSL Behring drove growth with a 6% revenue increase; Privigen, Hizentra, Albumin, and hemophilia sales all rose.

• Seqirus revenue increased 2%, offset by lower US immunization rates but supported by pandemic response opportunities.

• Vifor revenue was up 8% with strong iron sales and nephrology launches.

• FY2026 revenue growth projected at 2%-3% and NPATA growth at 4%-7%, excluding restructuring costs.

Board and executive committee updates

• Dr. Megan Clark and Ms. Marie McDonald retired; Dr. Brian Daniels and Mr. Cameron Price were elected as new directors.

• Announced future appointments: Mr. Costa Saroukos and Mr. Gordon Naylor to join the board in December 2025.

• Dr. Mary Oates appointed COO, Andy Schmeltz as CCO, and Ken Lim as CFO following Joy Linton’s retirement.